AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today its financial results for the quarter and year ended December 31, 2006. The results were consistent with the Company’s expectations and a result of its continued progress in both its research and development and clinical and regulatory programs.
